| Authors: |
Lim K; Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Department of Physiology, Anatomy and Microbiology, La Trobe University, Bundoora, VIC, Australia., Burke SL; Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Marques FZ; Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Clayton, VIC, Australia., Jackson KL; Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Gueguen C; Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Sata Y; Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Human Neurotransmitters Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Faculty of Medicine, Nursing and Health Sciences, Central Clinical School, Monash University, Melbourne, VIC, Australia.; Department of Cardiology, Alfred Hospital, Melbourne, VIC, Australia., Armitage JA; School of Medicine (Optometry), and IMPACT Institute for Innovation in Physical and Mental Health and Clinical Translation, Faculty of Health, Deakin University, Waurn Ponds, VIC, Australia., Head GA; Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Department of Pharmacology, Monash University, Clayton, VIC, Australia. |
